Electronic Drug Delivery       WEDD® Platform       WEDD® Strengths       WEDD® Targets        News Release

The Company’s primary strategy is to develop WEDD product applications as value-added new drug forms via NDA approval for targeted therapeutic indications. Current targets include pain management/anesthesia, anti-inflammatory, anti-emetic, anti-migraine and vasodilation therapeutic classes, among others. The Company will partner via license and co-develop with pharmaceutical companies for specific targeted drugs and indications. WEDD® Current Therapeutic Targets Therapeutic Area Indication Delivery Mode Drugs Pain Management -Chronic Pain (Cancer) -Acute Post-Op Pain (outpatient surgery) Systemic Systemic, Localized & Regionalized Fentanyl Fentanyl, “caines” & others Pain Management & Anesthesia Dermal and Pain Anesthesia Localized Lidocaine, prilocaine & others Anti-Inflammatory Tendonitis, bursitis, fascitis, arthritis Localized Steroids (dexamethasone) NSAID’s Anti-Emetic -Post-Op Nausea & Vomiting (outpatient surgery) -Chemotherapy Nausea & Vomiting Systemic Systemic 5HT3’s & others 5HT3’s & others Anti-Migraine Migraine Pain & Symptoms Systemic “Triptans” & others Vasodilation Peripheral Vascular Disease (diabetic neuropathy) Localized & Systemic Prostaglandin E1 & others Anti-Thrombosis Prevention of clots (post-surgery deep vein thrombosis DVT) Systemic Low weight heparin, warfarin & others Business Development Opportunities Please Contact: Robert Z. Arnold Vice President, Marketing, Sales & Business Development 2520 Pilot Knob Road Suite 100 Mendota Heights, MN 55120 Phone: 1-866-467-2824 Fax: 1-651-730-1013 Email: rarnold@travantipharma.com

home      Rev 1

Copyright © 2002, Travanti Pharma Inc. 1-866-467-2824